{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024139","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.362029+00:00","generated_at":"2026-06-21T22:34:09.387750+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Larimar Q3 net loss narrows to $8.3M; Phase 2 CTI-1601 trial resumes with data expected 2H 2023","bullets":["Net loss $8.3M ($0.37/share) in Q3 2022 vs $16.8M ($0.92) in Q3 2021; 9-month net loss $25.9M ($1.32) vs $41.5M ($2.48).","Cash and marketable securities $124.7M at Sept 30, providing projected cash runway into 2H 2024.","FDA lifted full clinical hold; Phase 2 25 mg dose exploration cohort in Friedreich's ataxia patients is ongoing; top-line data expected 2H 2023.","Net proceeds of ~$75.2M raised in September 2022 underwritten offering; Deerfield Management participated.","U.S. Patent No. 11,459,363 issued for CTI-1601 composition of matter, covering into July 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024139","json":"https://secwatch.observer/filing/0000950170-22-024139.json","markdown":"https://secwatch.observer/filing/0000950170-22-024139.md","text":"https://secwatch.observer/filing/0000950170-22-024139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/0000950170-22-024139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/lrmr-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:34:09.387750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c44411336ae0b36391688a1393ff827c73d21251","claim":"Larimar Therapeutics, Inc. reported the nine months ended September 30, 2022 results: net income a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share, EPS $1.32 per share.","evidence_excerpt":"The Company reported a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share, compared to a net loss of $41.5 million, or $2.48 per share, for the nine months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/0000950170-22-024139-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Net income","value":"a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share"},{"label":"EPS","value":"$1.32 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f4d141de40ec5cb7bb8135fe9794c0cf39bdf786","claim":"Larimar Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share, EPS $0.37 per share.","evidence_excerpt":"The Company reported a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share, compared to a net loss of $16.8 million, or $0.92 per share, for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/0000950170-22-024139-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share"},{"label":"EPS","value":"$0.37 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}